东北制药(000597) - 2017 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders surged by 1,269.56% to CNY 40,166,219.71 for the reporting period [8]. - Operating revenue rose by 7.14% to CNY 1,425,755,444.85 compared to the same period last year [8]. - Basic earnings per share increased by 700.00% to CNY 0.08 for the reporting period [8]. - The company reported a net profit of CNY 79,860,938.67 for the year-to-date, reflecting a 1,213.92% increase compared to the same period last year [8]. - The net profit after deducting non-recurring gains and losses was CNY 36,462,110.45, a 542.56% increase year-on-year [8]. - The net profit for the period was 95.15 million, an increase of 353.86% compared to the previous period, driven by increased revenue and gross profit [15]. Cash Flow and Assets - The net cash flow from operating activities showed a significant decline of 10,761.24% to -CNY 106,837,076.87 year-to-date [8]. - Cash received from sales of goods and services during the period was 3,657.79 million, an increase of 38.09% compared to the previous period, mainly due to increased sales [15]. - Cash paid for purchasing goods and services during the period was 2,524.62 million, an increase of 59.74% compared to the previous period, primarily due to increased sales and rising raw material costs [15]. - The balance of undistributed profits at the end of the period was 40.01 million, an increase of 202.21% compared to the beginning of the year, reflecting a significant increase in the company's profitability [15]. Shareholder Information - The total number of shareholders at the end of the reporting period was 36,553 [11]. - The largest shareholder, Northeast Pharmaceutical Group Co., Ltd., holds 21.05% of the shares [11]. - Cash received from minority shareholders for capital increase was 10.65 million, an increase of 77.42% compared to the previous period, indicating more capital inflow from minority shareholders [21]. Asset Changes - Total assets increased by 5.13% to CNY 10,291,946,867.33 compared to the end of the previous year [8]. - Accounts receivable at the end of the period amounted to 1,451.01 million, an increase of 34.54% compared to the beginning of the year, primarily due to increased sales [15]. - The balance of construction in progress at the end of the period was 630.07 million, an increase of 52.87% compared to the beginning of the year, mainly due to the implementation of the second phase of the relocation project [15]. - The balance of other non-current assets at the end of the period was 162.59 million, an increase of 51.98% compared to the beginning of the year, mainly due to increased engineering prepayments [15]. Investment and Returns - The weighted average return on equity was 1.69%, up from 1.57% at the end of the previous year [8]. - Investment income for the period was 8.13 million, an increase of 1,440.49% compared to the previous period, mainly due to increased income from matured financial products [15]. - The company has not engaged in any securities or derivative investments during the reporting period [23][24].